BridgeBio Oncology (BBOT) Form 3: Two Director Stock Options Detailed

Rhea-AI Filing Summary

Form 3 filing by Tipirneni Praveen P. reports initial beneficial ownership in BridgeBio Oncology Therapeutics, Inc. (Ticker: BBOT). The filing, covering an event dated 08/11/2025, identifies the reporting person as a director and discloses two stock option awards exercisable for common stock. One option covers 81,069 shares with an exercise price of $5.18 and an exercisable date shown as 12/25/2034. The second option covers 4,855 shares with an exercise price of $7.88 and an exercisable date shown as 04/02/2035. The filing states each option vests in 1/48th monthly installments starting November 11, 2024 (first option) and April 4, 2025 (second option), subject to continuous service. The form is signed by an attorney-in-fact on 08/18/2025.

Positive

• Timely disclosure of beneficial ownership by a director pursuant to Section 16
• Specific option details provided: number of shares, exercise prices, exercisable dates and vesting schedules

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine director disclosure of equity compensation; vesting tied to service, no unusual governance red flags.

The filing is a standard initial Form 3 showing a director-level reporting person receiving two stock options. Vesting over 48 months with monthly installments is a common executive/director compensation structure that aligns retention incentives with continued service. There is no indication of accelerated vesting, related-party transfers, or unusual beneficial ownership arrangements in the document. From a governance perspective, the disclosure meets Section 16 requirements and provides transparency on potential future dilution tied to option exercises.

Securities Analyst

TL;DR: Non-material ownership disclosure for investors; option quantities and strike prices are specified, but no immediate market impact.

The reported options total 85,924 underlying shares (81,069 + 4,855) with exercise prices of $5.18 and $7.88. The exercisability dates listed are several years out, and vesting is gradual (1/48th monthly), indicating limited near-term dilution. The Form 3 does not disclose exercised or sold shares, cash proceeds, or any pledging of the securities. For valuation or dilution modeling, these options should be treated as potential future dilution subject to continued service rather than immediate share supply.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tipirneni Praveen P.

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	12/25/2034	Common Stock	81,069	$5.18	D
Stock Option (Right to Buy)	(2)	04/02/2035	Common Stock	4,855	$7.88	D

Explanation of Responses:

1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of November 11, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date.

2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 4, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan,Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 3 for BridgeBio Oncology Therapeutics (BBOT)?

The Form 3 was filed on behalf of Tipirneni Praveen P., identified as a director of the issuer.

What securities are disclosed on this Form 3 for BBOT?

Two stock options are disclosed: 81,069 shares at $5.18 and 4,855 shares at $7.88, exercisable on the dates shown in the filing.

When did the event requiring this Form 3 occur?

The form lists the date of the event as 08/11/2025 and the attorney-in-fact signed the filing on 08/18/2025.

What are the vesting terms for the options disclosed?

Each option vests in 1/48th of the shares in substantially equal monthly installments starting November 11, 2024 (first option) and April 4, 2025 (second option), subject to continuous service.

Do these disclosures indicate immediate dilution to BBOT shareholders?

No. The options vest monthly over four years and have future exercisable dates, so they represent potential future dilution contingent on vesting and exercise.